Molecular Insight fills executive ranks

Jul 20, 2005

Molecular Insight Pharmaceuticals of Cambridge, MA, has appointed Bob Gallahue as its chief financial officer and Priscilla Harlan as vice president, corporate communications.

Gallahue will oversee financial planning and administration and communications for the company, and Harlan will oversee public relations, investor relations, and scientific communications, Molecular Insight said.

By AuntMinnie.com staff writers
July 21, 2005

Related Reading

Molecular Insight hires new vice presidents, June 1, 2005

Molecular Insight raises $28 million, June 1, 2005

Molecular Insight, University of Maryland get NIH grant, August 27, 2004

Copyright © 2005 AuntMinnie.com

Latest in Molecular Imaging
Breast Mol
FES-PET could save $142M in breast cancer costs
May 20, 2024
Driving the future of PET/CT.
Sponsored
Driving the future of PET/CT.
April 17, 2024
Individualized parametric z-score maps of the brain showing glial activity load in the brain, compared among individuals with secondary progressive MS (SPMS) (top row), relapsing-remitting MS (RRMS) (middle row), and a healthy control (HC) (bottom row) in transaxial, sagittal, and coronal sections. Image courtesy of Clinical Nuclear Medicine.
PET reveals ‘smoldering’ brain inflammation in patients treated for MS
April 29, 2024
Liver Cancer
Dual-tracer PET/CT shows promise in liver cancer patients
April 26, 2024
Related Stories
2005 07 13 16 02 26 706
Nuclear Medicine
Cervical tumor volumes on FDG-PET predict treatment outcome
2002 03 13 15 53 59 706
Nuclear Medicine
Can SPECT/CT revitalize nuclear medicine?
2005 06 20 15 36 30 706
Nuclear Medicine
3D rendering captures SNM's Image of the Year
Driving the future of PET/CT.
Sponsor Content
Driving the future of PET/CT.
More in Molecular Imaging
FES-PET could save $142M in breast cancer costs
By Will Morton
Adding F-18 fluroestradiol (FES)-PET/CT imaging to standard of care tests in women with suspected estrogen receptor (ER)-positive breast cancer could save millions.
May 20, 2024
Breast Mol
New guidance issued on PET/CT imaging in breast cancer
By Will Morton
The world’s top nuclear medicine societies have issued international guidelines on the role of PET/CT in patients with invasive ductal carcinoma.
May 17, 2024
Breast Mol
PET reveals ‘smoldering’ brain inflammation in patients treated for MS
By Will Morton
PET brain scans show persistent brain inflammation in patients with multiple sclerosis (MS), despite being treated with therapies.
April 29, 2024
Individualized parametric z-score maps of the brain showing glial activity load in the brain, compared among individuals with secondary progressive MS (SPMS) (top row), relapsing-remitting MS (RRMS) (middle row), and a healthy control (HC) (bottom row) in transaxial, sagittal, and coronal sections. Image courtesy of Clinical Nuclear Medicine.
Dual-tracer PET/CT shows promise in liver cancer patients
By Will Morton
Dual-tracer PET/CT appears valuable for improving tumor staging in patients with hepatocellular carcinoma being evaluated for treatment.
April 26, 2024
Liver Cancer
SPECT/CT predicts foot amputations in diabetics
By Will Morton
Technetium-99m white blood cell SPECT/CT imaging may be useful for identifying diabetic patients at risk of amputations due to foot infections.
April 24, 2024
Examples in two patients. (Top) Abnormal leukocyte accumulation was observed in the right 1st to 5th toes, with the radioactive lesions extending to the bone, indicating osteomyelitis (left panel, MIP image; right panel, axial SPECT/CT). Two spherical VOIs were drawn on diabetic foot infections (DFIs) and the highest SUVmax was 4.2 (higher than the cutoff of 1.1) Despite intensive treatment, the infection progressed, leading to the patient undergoing right below knee amputation 43 days after SPECT/CT. (Bottom) Mild focal abnormal leukocyte accumulation was detected in the right 3rd and 4th toes. The lesions were in contact with the bone, which raised a suspicion of osteomyelitis (left panel, MIP image; right panel, axial SPECT/CT). A circular VOI was drawn on DFIs and the SUVmax was 1.0 (lower than the cutoff of 1.1). After 10 weeks of antibiotic treatment, the infection was successfully resolved, and the foot was preserved. Image and caption courtesy of Scientific Reports.
PET/CT superior to MRI for detecting spinal bone metastases
By Will Morton
Gallium-68 DOTATATE PET/CT appears to be the best approach for detecting spinal bone metastases in patients with certain neuroendocrine tumors.
April 23, 2024
Ppgl 167 250
Neuroimaging detects blast exposure brain injuries in U.S. soldiers
By Will Morton
A battery of MRI and PET neuroimaging tests show patterns of brain injury in active-duty U.S. soldiers caused by repeated blast exposures.
April 22, 2024
Military
PET/MRI reveals sex differences in patients with autism
By Will Morton
PET/MRI shows that young women with autism spectrum disorder have increased brain metabolism associated with translocator protein.
April 18, 2024
Tspo Thumbnail
PET tracer for gliomas under expedited review
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to Telix Pharmaceuticals’ PET radiotracer F-18 floretyrosine (Pixclara) for imaging progressive or recurring gliomas.
April 17, 2024
Gliomas
FAPI-PET shows promise in patients with lung cancer
By Will Morton
FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans.
April 15, 2024
F-18 FDG and Ga-68 FAPI-46 images of a 51-year-old woman with adenocarcinoma with lepidic growth pattern in right upper lobe. (A) Maximum-intensity-projection PET images. The lesion had F-18 FDG uptake below blood pool level but was strongly Ga-68 FAPI-46-positive. CT-guided biopsy led to pathologic diagnosis of adenocarcinoma, and the patient was treated by stereotactic body radiation therapy because of functional inoperability. Image courtesy of the Journal of Nuclear Medicine.
Vision transformer AI model boosts PET/CT imaging of cancer
By Will Morton
A vision transformer AI model outperformed convolutional neural networks when classifying tumors on PET/CT images as benign or malignant.
April 12, 2024
Predictions and Grad-CAMs of ViT-based models on sample PET/CT, PET, and CT test images from the “positive” class. ViT was fine-tuned using training data for each modality. The bounding boxes depicted in the figure indicate malignant lesions. The top row of the Grad-CAMs shows important areas for “positive” predictions, and the bottom row shows areas for “negative” predictions. Image courtesy of Scientific Reports.
Can AI improve sustainability in nuclear medicine?
Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.
April 9, 2024
ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.
Page 1 of 593
Next Page